Article
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
Investigational new drugs - 1 Oct 2022
Kunimasa Kei, Sugimoto Naotoshi, Tamiya Motohiro, Inoue Takako, Kawamura Takahisa, Kanzaki Ryu, Okami Jiro, Nishino Kazumi
Abstract excerpt
It has been reported that the efficacy of EGFR-TKI is predicted, not by which exon of the EGFR gene is mutated, but by the structural change in the EGFR protein due to the mutation. Here, we present an EGFR-mutated lung cancer patient with a 13-year history of anticancer treatment, in which EGFR ex.19 deletion (E746_S752 > V) and G724S mutations were detected by liquid biopsy during 12th line afatinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
